These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 27401863)

  • 21. What is the efficacy of switching to weekly pegvisomant in acromegaly patients well controlled on combination therapy?
    Muhammad A; van der Lely AJ; O'Connor RD; Delhanty PJ; Dal J; Dallenga AH; Feelders RA; Janssen JA; Jorgensen JO; Neggers SJ
    Eur J Endocrinol; 2016 May; 174(5):663-7. PubMed ID: 26903550
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety of long-term treatment with Pegvisomant: analysis of Spanish patients included in global ACROSTUDY.
    Bernabeu I; Pico A; Venegas E; Aller J; Alvarez-Escolá C; García-Arnés JA; Marazuela M; Jonsson P; Mir N; García Vargas M;
    Pituitary; 2016 Apr; 19(2):127-37. PubMed ID: 26553421
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alternate-day administration of pegvisomant maintains normal serum insulin-like growth factor-I levels in patients with acromegaly.
    Jehle S; Reyes CM; Sundeen RE; Freda PU
    J Clin Endocrinol Metab; 2005 Mar; 90(3):1588-93. PubMed ID: 15585549
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial.
    Higham CE; Atkinson AB; Aylwin S; Bidlingmaier M; Drake WM; Lewis A; Martin NM; Moyes V; Newell-Price J; Trainer PJ
    J Clin Endocrinol Metab; 2012 Apr; 97(4):1187-93. PubMed ID: 22278424
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY.
    Buchfelder M; van der Lely AJ; Biller BMK; Webb SM; Brue T; Strasburger CJ; Ghigo E; Camacho-Hubner C; Pan K; Lavenberg J; Jönsson P; Hey-Hadavi JH
    Eur J Endocrinol; 2018 Dec; 179(6):419-427. PubMed ID: 30325178
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Does pegvisomant treatment expertise improve control of resistant acromegaly? The Italian ACROSTUDY experience.
    Cannavo S; Bogazzi F; Colao A; De Marinis L; Maffei P; Gomez R; Graziano E; Monterubbianesi M; Grottoli S;
    J Endocrinol Invest; 2015 Oct; 38(10):1099-109. PubMed ID: 25916431
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly.
    Chiloiro S; Mazziotti G; Giampietro A; Bianchi A; Frara S; Mormando M; Pontecorvi A; Giustina A; De Marinis L
    Pituitary; 2018 Jun; 21(3):302-308. PubMed ID: 29397538
    [TBL] [Abstract][Full Text] [Related]  

  • 28. All-cause mortality in patients with acromegaly treated with pegvisomant: an ACROSTUDY analysis.
    Tritos NA; Mattsson AF; Vila G; Biller BMK; Klibanski A; Valluri S; Hey-Hadavi J; Kelepouris N; Jimenez C
    Eur J Endocrinol; 2020 Mar; 182(3):285-292. PubMed ID: 31917681
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prediction of therapy response in acromegalic patients under pegvisomant therapy within the German ACROSTUDY cohort.
    Sievers C; Baur DM; Schwanke A; Buchfelder M; Droste M; Mann K; Stalla GK
    Pituitary; 2015 Dec; 18(6):916-23. PubMed ID: 26224528
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant.
    Sesmilo G; Fairfield WP; Katznelson L; Pulaski K; Freda PU; Bonert V; Dimaraki E; Stavrou S; Vance ML; Hayden D; Klibanski A
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1692-9. PubMed ID: 11932303
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hypertension in Acromegaly in Relationship to Biochemical Control and Mortality: Global ACROSTUDY Outcomes.
    Vila G; Luger A; van der Lely AJ; Neggers SJCMM; Webb SM; Biller BMK; Valluri S; Hey-Hadavi J
    Front Endocrinol (Lausanne); 2020; 11():577173. PubMed ID: 33329385
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal.
    Parkinson C; Kassem M; Heickendorff L; Flyvbjerg A; Trainer PJ
    J Clin Endocrinol Metab; 2003 Dec; 88(12):5650-5. PubMed ID: 14671148
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pregnancy in acromegaly patients treated with pegvisomant.
    van der Lely AJ; Gomez R; Heissler JF; Åkerblad AC; Jönsson P; Camacho-Hübner C; Kołtowska-Häggström M
    Endocrine; 2015 Aug; 49(3):769-73. PubMed ID: 25542184
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Effect of the Exon-3-Deleted Growth Hormone Receptor on Pegvisomant-Treated Acromegaly: A Systematic Review and Meta-Analysis.
    Franck SE; Broer L; van der Lely AJ; Kamenicky P; Bernabéu I; Malchiodi E; Delhanty PJD; Rivadeneira F; Neggers SJCMM
    Neuroendocrinology; 2017; 105(2):131-140. PubMed ID: 27513761
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined treatment of somatostatin analogues with pegvisomant in acromegaly.
    Franck SE; Muhammad A; van der Lely AJ; Neggers SJ
    Endocrine; 2016 May; 52(2):206-13. PubMed ID: 26661938
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant.
    Trainer PJ; Drake WM; Katznelson L; Freda PU; Herman-Bonert V; van der Lely AJ; Dimaraki EV; Stewart PM; Friend KE; Vance ML; Besser GM; Scarlett JA; Thorner MO; Parkinson C; Klibanski A; Powell JS; Barkan AL; Sheppard MC; Malsonado M; Rose DR; Clemmons DR; Johannsson G; Bengtsson BA; Stavrou S; Kleinberg DL; Cook DM; Phillips LS; Bidlingmaier M; Strasburger CJ; Hackett S; Zib K; Bennett WF; Davis RJ
    N Engl J Med; 2000 Apr; 342(16):1171-7. PubMed ID: 10770982
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term experience of pegvisomant therapy as a treatment for acromegaly.
    Higham CE; Chung TT; Lawrance J; Drake WM; Trainer PJ
    Clin Endocrinol (Oxf); 2009 Jul; 71(1):86-91. PubMed ID: 19018786
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly.
    Jawiarczyk A; Kałuzny M; Bolanowski M; Bednarek-Tupikowska G
    Neuro Endocrinol Lett; 2008 Aug; 29(4):571-6. PubMed ID: 18766168
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly.
    Trainer PJ; Ezzat S; D'Souza GA; Layton G; Strasburger CJ
    Clin Endocrinol (Oxf); 2009 Oct; 71(4):549-57. PubMed ID: 19438906
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly.
    Neggers SJ; van Aken MO; Janssen JA; Feelders RA; de Herder WW; van der Lely AJ
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4598-601. PubMed ID: 17895318
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.